BHCQT87Bausch Health Companies Inc.·NYSE
8.02-2.20%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-2.27Insider Own46.63%Shs Outstand373.99MPerf Week26.30%
Market Cap3.00BForward P/E1.82EPS next Y4.40Insider Trans-0.04%Shs Float331.34MPerf Month38.28%
Enterprise Value21.21BPEG—EPS next Q—Short Float2.49%Perf Quarter24.53%
Income-841.00MP/S0.27EPS this Y23.24%Short Ratio2.51Perf Half Y45.03%
Sales11.11BP/B—EPS next Y-7.90%ROA-3.30%Short Interest8.24MPerf YTD15.40%
Book/sh-0.91P/C1.21EPS next 5Y-7.18%ROE—52W High9.04 -11.28%Perf Year21.33%
Cash/sh6.64P/FCF1.64EPS past 3/5Y—ROIC14.38%52W Low4.33 85.22%Perf 3Y19.17%
Dividend Est.—EV/EBITDA8.88Sales past 3/5Y8.11% 5.04%Gross Margin72.62%Volatility9.82% 5.44%Perf 5Y-72.35%
Dividend TTM—EV/Sales1.91EPS Y/Y TTM-336.46%Oper. Margin27.97%ATR (14)0.44Perf 10Y-63.48%
Dividend Ex-DateNov 10, 2010Quick Ratio1.22Sales Y/Y TTM10.81%Profit Margin-7.57%RSI (14)68.98Recom2.61
Dividend Gr. 3/5Y-13.82% 20.68%Current Ratio1.56EPS Q/Q52.59%SMA2022.07%Beta0.27Target Price8.50
Payout0.00%Debt/Eq—Sales Q/Q9.70%SMA5027.96%Rel Volume1.55Prev Close8.20
Employees20,300LT Debt/Eq—EarningsFeb 17SMA20040.61%Avg Volume3.07MPrice8.02
IPO DateMar 29, 1994Option/ShortYes / YesEPS/Sales Surpr.41.60% —Net Debt/EBITDA7.62Volume4,764,239Change-2.20%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedJefferiesHold$16 → $8.00
Oct-08-26ReiteratedRBC CapitalSector Perform$10 → $9.00
Jan-07-26ReiteratedTruist SecuritiesHold$7.00 → $8.00
Dec-08-25InitiatedBarclaysEqual Weight$8.00
Feb-06-25DowngradeJefferiesBuy → Hold
Oct-23-24ReiteratedRBC CapitalSector Perform$8.50 → $10
Aug-02-24DowngradePiper SandlerNeutral → Underweight
Jul-25-24ReiteratedTruist SecuritiesHold$7.00
Jul-10-24InitiatedRaymond JamesMarket Perform on Xifaxan risk$8.00
Apr-29-24ReiteratedPiper SandlerNeutral$6.00 → $9.00
Latest News· Times ET
Oct-29-26
Oct-28-26
Oct-26-26
Oct-22-26
Oct-19-26
Oct-16-26
Oct-12-26
Company

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue11,11310,2669,6258,757—————
Cost of Goods Sold Incl. D&A3,0433,0132,7822,559—————
Gross Profit8,0707,2536,8436,198—————
Selling, General and Administrative Excl. Other3,4843,4383,2832,895—————
Research and Development528629634604—————
Other Operating Expense9501,0011,3801,736—————
Operating Income3,1082,1851,546963—————
Interest Expense1,5931,6041,3881,328—————
Unusual Expense
—————————
Non-Operating Income (Expense)-1,868-2149-25—————
Net Income Before Taxes-353367167-390—————
Income Taxes475247239221—————
Consolidated Net Income-841157-46-592—————
Net Income From Continuing Operations-828120-72-611—————
Net Income-841157-46-592—————
EPS (Recurring)-2.270.43-0.13-1.62—————
EPS (Basic, Before Extraordinaries)-2.270.43-0.13-1.62—————
EPS (Diluted)-2.270.43-0.13-1.62—————
EBITDA2,3903,1793,1342,885—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—16.16———————
Price To Sales Ratio0.270.250.310.33—————
Gross Margin72.6270.6571.1070.78—————
Operating Margin27.9721.2816.0611.00—————
Net Margin-7.571.53-0.48-6.76—————
Shares Outstanding376371368365—————
Market Capitalization3,0162,5782,9662,927—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$9.58$8.13$6.67$5.21$3.76● Close Price0.00M3.91M7.81M11.72M15.63MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lenar Aimee J.President, US PharmaAug 19 '26Sale7.0336,827258,894334,853Aug 20
Lee Frank D.DirectorMay 19 '26Sale5.4324,456132,79649,339May 20
Carson SeanaEVP, General CounselMar 03 '26Sale5.774,42025,503616,761Mar 03
Carson SeanaEVP, General CounselMar 02 '26Sale5.786,85639,628776,076Mar 03
Carson SeanaEVP, General CounselFeb 27 '26Sale5.958,38849,909809,258Feb 27
PAULSON & CO. INC.10% OwnerNov 25 '25Buy6.252,500,00015,625,00073,255,869Nov 28
Carson SeanaEVP, General CounselSep 08 '25Sale7.3113,37097,735499,585Sep 08
Lee Frank D.DirectorAug 21 '25Sale7.6615,912121,88673,795Aug 22
Paulson JohnDirectorAug 14 '25Buy9.0034,721,118312,490,06270,755,869Aug 14
Paulson JohnDirectorAug 13 '25Buy7.0686,409610,04836,034,751Aug 13
Paulson JohnDirectorAug 12 '25Buy6.881,156,6407,957,68335,948,342Aug 13
Paulson JohnDirectorAug 11 '25Buy6.352,000,00012,700,00034,791,702Aug 13
Paulson JohnDirectorJun 13 '25Buy5.943,564,05921,170,51032,791,702Jun 17
Paulson JohnDirectorJun 12 '25Buy5.471,005,3765,499,40729,227,643Jun 12
Paulson JohnDirectorJun 11 '25Buy5.241,029,0985,392,47428,222,267Jun 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.